Baiyang Medicine plans to make a strategic investment in Beihai Kangcheng.

On August 13th, Interface News learned that Beihai Kangcheng and Baiyang Pharmaceuticals have reached a share subscription agreement. Baiyang Pharmaceuticals will subscribe to approximately 74.97 million shares worth about 100 million Hong Kong dollars at a price of 1.34 Hong Kong dollars per share. At the same time, Beihai Kangcheng also signed an exclusive commercialization service agreement with Baiyang Pharmaceuticals. Subsidiaries of Baiyang Pharmaceuticals will have the promotion rights for specific products under Beihai Kangcheng in mainland China, Hong Kong, and Macau.